Hyrich, KL;
Machado, PM;
(2021)
Rheumatic disease and COVID-19: epidemiology and outcomes.
Nature Reviews Rheumatology
, 17
pp. 71-72.
10.1038/s41584-020-00562-2.
Preview |
Text
Machado_Rheumatic disease and COVID-19- epidemiology and outcomes_AAM.pdf - Accepted Version Download (250kB) | Preview |
Abstract
Patients with rheumatoid arthritis, systemic lupus erythematosus or psoriasis, when analysed as a combined group, might have a slightly increased risk of death from COVID-19 compared to those without these diseases, although the role of disease activity and treatment in this risk estimation was not taken into account2. Treatment with cytokine inhibitors could reduce the risk of SARS-SoV-2 infection (as measured by development of SARS-CoV-2 antibodies), although the mechanisms of this protective effect are not clear3. Chronic use of glucocorticoids at moderate or high doses (≥10 mg per day prednisolone or equivalent) is associated with hospitalization for severe COVID-194.
Archive Staff Only
 |
View Item |
